CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the impact of dystrophin mutations on both muscle and central nervous system function in Duchenne muscular dystrophy. It aims to develop genetic therapies that could alleviate associated neurodevelopmental issues in affected patients.
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in childhood, with more than 25,000 patients in Europe.
It is due to mutations in the DMD gene that preclude the production of the protein dystrophin.
In addition to the progressive muscle weakness, 50% of affected individuals have debilitating central nervous system (CNS) co-morbidities, including intellectual disability, neurodevelopmental problems encompassing autism, Attention Deficit Hyperactivity Disorder and Obsessive…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Italy, Ferrara
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Denmark, Hillerod
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
